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Resistance to carbapenems in  Pseudomonas aeruginosa is a
major issue since that species is intrinsically resistant to many
antibiotics and therefore, as soon as some acquired resistance
traits occur, carbapenems become rapidly the ultimate therapeu-
tic options.1 Carbapenem resistance in P. aeruginosa may  occur
through the loss of an outer-membrane protein named OprD that
results from mutations or truncations in the corresponding gene.2
In Europe, that mechanism accounts for 15–20% of the imipenem-
resistant P. aeruginosa isolates. It is not transmissible since it is
chromosomally-encoded and interferes with imipenem suscepti-
bility only, meropenem and doripenem as well as broad-spectrum
cephalosporins remaining effective against OprD-deﬁcient strains
(if no additional acquired mechanism). However, the acquisition of
carbapenemase genes is  another mechanism of carbapenem resis-
tance in P. aeruginosa that is  increasingly identiﬁed wordwide.3
That resistance trait is  more worrisome since it corresponds
to genes acquired through horizontal gene transfers that may
disseminate, and impacts all carbapenem molecules that are
all hydrolyzed by those enzymes. In P. aeruginosa, carbapene-
mases are mainly metallo--lactamases (MBLs) that hydrolyze
all carbapenems very efﬁciently.4 They are not inhibited by -
lactamase inhibitors such as clavulanic acid and tazobactam and
also confer resistance to other -lactams such as broad-spectrum
cephalosporins.
Therefore, an accurate and rapid detection of carbapenemase
production in P. aeruginosa is extremely important. Such rapid
detection may  contribute to facilitate the antibiotic stewardship
and treatment of infected patients and to prevent the further spread
of those carbapenem-resistant isolates.
Therefore, in order to optimize infection control and antimi-
crobial therapy, advances in detection methods are crucial. Use
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of molecular biology and in particular PCR-based techniques is
being the key-approach for rapid and accurate identiﬁcation of
those resistance traits. The main advantages of molecular tech-
niques are sensitivity, speciﬁcity, and the relative rapidity of these
methods. Without molecular techniques in routine laboratories,
identiﬁcation of resistance mechanisms is  often fastidious and
time-consuming.
However, there are some drawbacks with those molecular tech-
niques, the main ones are: (i) they are expensive, (ii) they do  require
some signiﬁcant expertise, (iii) they do not  fully replace the antibi-
ogram since they only target some speciﬁc molecular determinants
but do not  evaluate the real susceptibility of the isolate to a  large
variety of drugs, (iv)  the correlation between gene identiﬁcation
and resistance is not always observed (gene expression and mod-
ulation), and (v) by deﬁnition they do not  identify the novel and
emerging resistance genes.
That  is  the reason why  biochemical and phenotypical methods
have still to be  considered as interesting tools. In the study per-
formed by Lucena et al. in this issue,5 phenotypic tests for detection
of MBL  production have been compared with an impressive collec-
tion of metallo--lactamase producers, mostly of the SPM type. The
double-disk synergy test (DDST), the Combined-Disk (CD) assay,
and the MBL E-test have been compared. They all show some advan-
tages and disadvantages, but one main shortcoming is the lack of
clear cut-off to accurately interpret the obtained results. Depend-
ing on the strain background (additional resistance mechanisms or
not), and on the user’s technical skills, variable results and inter-
pretations may  be observed.
We believe that those diagnostic techniques, in order to  be
used, must not  only be  affordable and rapid, but overall must be
easy to perform and interpret. Routine laboratories cannot rely
on complicated screening strategies that, in  addition, may  provide
difﬁcult-to-interpret results. Efforts must be placed in developing
those tests that may  be used in  any clinical laboratory, and not only














One recently developed technique aiming to rapidly iden-
tify carbapenemase producers, either in  Pseudomonas spp. and in
Enterobacteriaceae,  is  the Carba NP test that corresponds to an
efﬁcient and reliable diagnostic tool for identiﬁcation of those
enzymes.6 The main advantages of this test are that it is extremely
rapid and costless, by contrast to  most of the other known tech-
niques. It actually represents a  breakthrough for detection of
carbapenemase producers with results obtained in less than two
hours, either directly from colonies but also from clinical samples
such as blood cultures and urines.7,8 Another major advantage of
this test is that it can be implemented in any clinical laboratories
due to its simplicity. It  is therefore well adapted to the current
needs, i.e. improving the hygiene control and the antimicrobial
therapy. In a country such as Brazil where the study from Lucena
et al. has been performed,5 it might really provide an added-value
since not only its low price and low-expertise requirement will
surely ﬁt to the expectations, but also the current and very worri-
some epidemiology (with huge dissemination of SPM-1-producing
P. aeruginosa strains all over the country9,10) will make it an essen-
tial tool.
Public health authorities around the world prompt to estab-
lish guidelines recommending strict and accurate monitoring of
antimicrobial resistance should facilitate the development and dis-
semination of those kinds of methods that correspond to  the needs
in the “real” daily life.
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